CD19 and precursor B-cell acute lymphoblastic leukemia: In pediatric B-ALL, B-cell recovery in peripheral blood within 3 months indicates a high risk of relapse with CD19 CAR-T cell therapy, which may be due to T-cell exhaustion [66].